What it's for (Indications)
- Etoposide, a semisynthetic derivative of podophyllotoxin, is primarily indicated for the treatment of refractory testicular tumors in adult patients, typically administered in combination with other approved chemotherapeutic agents.
- It is also a cornerstone therapeutic agent for the management of small cell lung cancer (SCLC), both in previously untreated and relapsed settings, where it is commonly utilized as part of combination regimens.
- Beyond these primary indications, etoposide is frequently incorporated into various multi-drug chemotherapy protocols for a range of other malignancies, including acute myeloid leukemia (AML), Hodgkin and non-Hodgkin lymphomas, gestational trophoblastic disease, and Kaposi's sarcoma, based on established clinical guidelines and evidence-based treatment protocols.
- Its broad spectrum of activity makes it a versatile agent in oncology, always used under strict medical supervision.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Etoposide dosage is highly individualized and depends on the specific cancer being treated, the patient's body surface area (BSA), renal and hepatic function, and whether it is administered as a single agent or part of a combination chemotherapy regimen. For intravenous administration in small cell lung cancer, typical doses range from 100-120 mg/m² daily for 3 to 5 days, repeated every 3 to 4 weeks. In refractory testicular cancer, common regimens involve doses of 50-100 mg/m² daily for 5 days, or 100 mg/m² on days 1, 3, and 5, also repeated every 3 to 4 weeks. Oral etoposide is available, with dosages generally being double the intravenous dose due to reduced bioavailability, such as 200 mg/m² daily for 5 days. Infusions must be administered slowly over a minimum of 30-60 minutes to minimize the risk of hypotension. Dose modifications are imperative in patients experiencing myelosuppression, or those with significant renal or hepatic impairment. All administration must be supervised by an oncologist with experience in antineoplastic therapy. |
Safety & Warnings
Common Side Effects
- Etoposide is associated with a range of dose-dependent and cumulative side effects, with myelosuppression being the most common and dose-limiting toxicity.
- This manifests as leukopenia, neutropenia, thrombocytopenia, and anemia, with nadir typically occurring 7-14 days post-treatment.
- Gastrointestinal toxicities are frequent and include moderate to severe nausea and vomiting, mucositis (oral and esophageal), diarrhea, and abdominal pain.
- Alopecia (hair loss) is common and usually reversible upon treatment cessation.
- Hypotension can occur if the intravenous infusion is administered too rapidly.
- Hypersensitivity reactions, characterized by chills, fever, tachycardia, bronchospasm, and dyspnea, have been reported and necessitate immediate medical intervention.
- Other adverse effects may include elevated liver enzymes, peripheral neuropathy, asthenia, and an increased risk of secondary malignancies, particularly acute myeloid leukemia (AML), often with a latency period of several years.
Serious Warnings
- Black Box Warning: Etoposide should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Severe myelosuppression with resulting infection or bleeding may occur.
- Etoposide carries several significant warnings due to its potent cytotoxic nature.
- Severe and dose-limiting myelosuppression is a critical concern, necessitating frequent complete blood count (CBC) monitoring before and during therapy to manage neutropenia, thrombocytopenia, and anemia, which can lead to life-threatening infections or hemorrhage.
- Dose reductions or treatment delays may be required.
- Rapid intravenous infusion can cause acute hypotension, therefore etoposide must be administered slowly over at least 30 to 60 minutes.
- Hypersensitivity reactions, including anaphylaxis, can occur and require close monitoring during and after infusion, with resuscitative equipment readily available.
- There is an established risk of developing secondary acute myeloid leukemia (AML), especially with cumulative doses, which patients should be counselled about.
- Etoposide is teratogenic and contraindicated in pregnancy due to embryo-fetal toxicity; effective contraception is mandatory for both male and female patients during and for a specified period after treatment.
- Dose adjustments are crucial for patients with renal or hepatic impairment.
- Caution is advised when administering etoposide concomitantly with other myelosuppressive agents or certain drugs that may alter its metabolism or excretion.
How it Works (Mechanism of Action)
Etoposide exerts its potent cytotoxic effects primarily through the inhibition of topoisomerase II, a critical nuclear enzyme responsible for managing DNA topology. Topoisomerase II functions to relieve torsional strain in DNA by creating transient double-strand breaks, passing another DNA strand through the break, and then re-ligating the DNA. Etoposide interferes with this process by forming a stable ternary complex with topoisomerase II and DNA, specifically by preventing the re-ligation of the broken DNA strands. This leads to an accumulation of irreversible double-strand DNA breaks, which are highly detrimental to cellular integrity. These unresolved DNA lesions activate signal transduction pathways that ultimately trigger programmed cell death (apoptosis) in rapidly proliferating cancer cells. Etoposide's activity is largely cell cycle-specific, with its maximal effect observed in the late S and G2 phases of the cell cycle, making it particularly effective against actively dividing malignant cells by disrupting DNA replication and repair processes.